Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria.
作者信息
Durando Paolo, Faust Saul N, Torres Antoni
机构信息
Department of Health Sciences, School of Medical and Pharmaceutical Sciences, Postgraduate School in Occupational Medicine, University of Genoa and Medical Surveillance Unit for Health Care Workers, Occupational Medicine Unit, IRCCS San Martino Hospital, Largo R. Benzi 10, 16132 Genoa, Italy.
NIHR Wellcome Trust Clinical Research Facility, University of Southampton, C Level, West Wing, Mailpoint 218, UK ; University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK.
出版信息
J Immunol Res. 2015;2015:934504. doi: 10.1155/2015/934504. Epub 2015 Aug 18.
Abstract
摘要
相似文献
1
Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria.抗细菌结合疫苗的免疫学特征及临床益处
J Immunol Res. 2015;2015:934504. doi: 10.1155/2015/934504. Epub 2015 Aug 18.
2
[A new vaccine concept: polysaccharide conjugate vaccines].一种新的疫苗概念：多糖结合疫苗
Ann Pharm Fr. 1999 May;57(3):223-31.
3
NMR assays for carbohydrate-based vaccines.基于碳水化合物的疫苗的核磁共振分析
J Pharm Biomed Anal. 2005 Aug 10;38(5):840-50. doi: 10.1016/j.jpba.2005.01.044. Epub 2005 Apr 13.
4
Challenges in immunisation against bacterial infection in children.儿童细菌性感染免疫接种面临的挑战。
Early Hum Dev. 2010 Nov;86(11):695-701. doi: 10.1016/j.earlhumdev.2010.08.010. Epub 2010 Sep 19.
5
T-cell dependent and T-cell independent antibody response to bacterial polysaccharides in patients with IgG2 deficiency.
Immunodeficiency. 1993;4(1-4):59-61.
6
Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.婴儿期接种蛋白多糖结合疫苗后的长期保护作用。
Expert Rev Vaccines. 2011 May;10(5):673-84. doi: 10.1586/erv.11.14.
7
The promise of conjugate vaccines for Africa.结合疫苗对非洲的前景。
Vaccine. 2007 Sep 3;25 Suppl 1:A108-10. doi: 10.1016/j.vaccine.2007.05.001. Epub 2007 May 21.
8
Bacterial polysaccharide-protein conjugate vaccines.细菌多糖-蛋白质结合疫苗
Br Med Bull. 2004 Aug 31;70:1-14. doi: 10.1093/bmb/ldh021. Print 2004.
9
[Fimbriae as a pathologic factor of bacteria and a carrier in conjugate vaccines].[菌毛作为细菌的致病因素及结合疫苗中的载体]
Postepy Hig Med Dosw. 2000;54(6):727-47.
10
Conjugate vaccines against group B Streptococcus types IV and VII.针对B族链球菌IV型和VII型的结合疫苗。
J Infect Dis. 2002 Jul 1;186(1):123-6. doi: 10.1086/341073. Epub 2002 Jun 14.
引用本文的文献
1
A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.一项在尼泊尔东部健康志愿者中进行的随机、观察者盲、对照 III 期临床试验，评估 Vi-白喉类毒素与 Vi-破伤风类毒素伤寒结合疫苗的安全性和免疫非劣效性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2203634. doi: 10.1080/21645515.2023.2203634.
2
Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.发展中国家疫苗生产能力建设：前进之路。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2020529. doi: 10.1080/21645515.2021.2020529. Epub 2022 Jan 27.
3
Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines. Toll 样受体靶向糖缀合物疫苗的最新进展。
Molecules. 2018 Jun 29;23(7):1583. doi: 10.3390/molecules23071583.
本文引用的文献
1
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.多糖结合疫苗预防成人肺炎球菌性肺炎。
N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.
2
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.全球、地区和国家按年龄、性别划分的 240 种死因的全死因和特定死因死亡率，1990-2013 年：2013 年全球疾病负担研究的系统分析。
Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.
3
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?肺炎球菌疫苗接种：我们目前了解到了什么，未来又能期待什么？
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):19-31. doi: 10.1007/s10096-014-2208-6. Epub 2014 Aug 23.
4
The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review.B 型流感嗜血杆菌疫苗和肺炎球菌结合疫苗对儿童脑膜炎死亡率的影响：一项系统评价
BMC Public Health. 2013;13 Suppl 3(Suppl 3):S21. doi: 10.1186/1471-2458-13-S3-S21. Epub 2013 Sep 17.
5
Pneumococcal infection in adults: burden of disease.成人肺炎链球菌感染：疾病负担。
Clin Microbiol Infect. 2014 May;20 Suppl 5:45-51. doi: 10.1111/1469-0691.12461. Epub 2014 Jan 24.
6
Haemophilus influenzae serotype a as a cause of serious invasive infections.甲型流感嗜血杆菌是严重侵袭性感染的病因。
Lancet Infect Dis. 2014 Jan;14(1):70-82. doi: 10.1016/S1473-3099(13)70170-1. Epub 2013 Nov 20.
7
Advances towards the prevention of meningococcal B disease: a multidimensional story.迈向脑膜炎奈瑟菌 B 型疾病预防的进展：一个多维度的故事。
J Infect. 2014 Jan;68 Suppl 1:S76-82. doi: 10.1016/j.jinf.2013.09.026. Epub 2013 Oct 16.
8
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.肺炎球菌多糖结合疫苗（与 CRM197 载体蛋白结合）在儿童和成人中的应用经验。
Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320.
9
U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.美国十年来肺炎球菌疫苗接种后肺炎住院情况。
N Engl J Med. 2013 Jul 11;369(2):155-63. doi: 10.1056/NEJMoa1209165.
10
Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000.全球、区域和国家儿童死亡原因：2010 年更新的系统分析及 2000 年以来的时间趋势
Lancet. 2012 Jun 9;379(9832):2151-61. doi: 10.1016/S0140-6736(12)60560-1. Epub 2012 May 11.
Zotero 插件